Chris directs public relations efforts for Bravo's biotechnology clients, drawing on his 10 years of experience in the healthcare, pharmaceutical and biotech industries with an emphasis on product and corporate communications, issues management, advocacy relations and communications, and regulatory communications.

Whether global market leaders or start-up biotechnology companies, Chris has extensive experience with FDA product approvals and launches, mature product promotion, business-to-business and direct-to-consumer communications, and issues management. Additionally, Chris has worked on several campaigns for leading device and diagnostic manufacturers in the diabetes category.

He was previously a communications manager at Cephalon, where, in addition to many successes, he secured a Newsweek cover story in March 2008 regarding the ongoing struggles of addiction in America. Prior to Cephalon, he was an account supervisor at Dorland Global Public Relations, where he managed national branded and unbranded public relations campaigns for clients including Cephalon, Proctor & Gamble Pharmaceuticals, sanofi-aventis, and Pennsylvania Bio.

While at Dorland, Chris managed a national osteoporosis education campaign aimed to raise awareness among young adult and middle-aged women on the signs of osteoporosis and methods for prevention. Within the campaign's first year, more than six million women nationwide received free osteoporosis screenings, consultations and education materials.

In addition, Chris has managed campaigns and work for many industry leaders such as GlaxoSmithKline, Eli Lilly, Amgen and Pfizer, where he was an integral part of the PR launch team for Zoloft.